
3rd Annual International Bladder Cancer Update
This is a one-day CME conference to discuss diangosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from and interact with expert, international faculty to improve knowledge and dtermine best treatment practices to improve patient outcomes.
The goal of this educational program is to equip healthcare professionals involved in the treatment of bladder cancer with up-to-date clinical knowledge and tools they need to best treat their patients. The program will compare and contrast the treatment of bladder cancer that is both muscle invasive (MIBC) and non-muscle invasive (NMIBC). From diagnosis and staging guidelines to treatment options in clinical trials, the program will give physicians a comprehensive review of the most up-to-date best practices in bladder cancer treatment.
Target Audience
This activity has been developed and is intended for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
Learning Objectives
The following are the learning objectives in CME format for this program. Upon completion of
this program, participants will be able to effectively address:
- new clinical practice guidelines
- Current best practices in prevention and screening of bladder cancer
- Updates on the use of biomarkers
- Promising therapies
- Issues and economic concerns in the tratment of low and high risk patients
- The sequencing of available therapies in 2016
Wednesday, January 23, 2019
11:00 AM – 2:00 PM Non-muscle Invasive Bladder Cancer Session
2:00 PM – 3:00 PM Invasive and Advanced Bladder Session: Part I
3:00 PM – 4:30 PM Invasive and Advanced Bladder Session: Part II
4:30 PM – 6:00 PM Invasive and Advanced Bladder Session: Part III

PROGRAM CHAIR
E. David Crawford, MD, University of Colorado, Denver School of Medicine, Aurora, CO
IBCU Co-Chairs:
Michael S. Cookson, MD, MMHC, University of Oklahoma College of Medicine, Norman, OK
Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT
IBCU FACULTY:
Peter Black, MD, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
Leonard G. Gomella, MD, Thomas Jefferson University, Philadelphia, PA
Ashish M. Kamat, MD, MBBS, FACS, The University of Texas, MD Anderson Cancer Center, Houston, TX
Seth P. Lerner, MD, Baylor College of Medicine, Houston, TX
Neal D. Shore, MD, Carolina Urologic Research Center, Atlantic Urology Clinics, LLC, Myrtle Beach, SC
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
MCW designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Available Credit
- 5.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 5.25 Hours of ParticipationHours of Participation credit.